|
5beta-dihydrotestosterone
|
DB07447 |
|
|
[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone
|
DB08778 |
|
|
AB192
|
DB06111 |
[AB192 is a DPP IV enzymatic activity inhibitor.] |
|
(2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid
|
DB07448 |
|
|
2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol
|
DB08779 |
|
|
N-[(1S)-1-(aminocarbonyl)-4-(ethanimidoylamino)butyl]benzamide
|
DB07449 |
|
|
Cenobamate
|
DB06119 |
[Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels.[L10653]
Cenobamate was granted FDA approval on 21 November 2019.[L10653]] |
|
4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol
|
DB08770 |
|
|
(5R)-2-[(2-Fluorophenyl)amino]-5-isopropyl-1,3-thiazol-4(5H)-one
|
DB08771 |
|
|
4-TERT-BUTYLBENZENESULFONIC ACID
|
DB07440 |
|
|
1alpha,24S-Dihydroxyvitamin D2
|
DB06117 |
[LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.] |
|
3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID
|
DB08772 |
|
|
3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID
|
DB07441 |
|
|
Eldelumab
|
DB06116 |
[MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.] |
|
2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
|
DB08773 |
|
|
(2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide
|
DB07443 |
|
|
1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine
|
DB08774 |
|
|
6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
|
DB07444 |
|
|
Benzoyl-tyrosine-alanine-fluoro-methyl ketone
|
DB08775 |
|
|
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
|
DB06124 |
[C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle.] |
